Vorinostat Completed Phase 2 Trials for Recurrent Ovarian Epithelial Cancer / Primary Peritoneal Cavity Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00132067Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer